DBV Technologies to Report Third Quarter 2022 Financial Results and Provide a Business Update
31 Outubro 2022 - 05:30PM
Montrouge, France, October 31, 2022
DBV Technologies to Report
Third Quarter 2022 Financial Results and Provide a Business
Update
DBV Technologies (Euronext: DBV – ISIN:
FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage
biopharmaceutical company, today announced that the Company will
host a conference call and live audio webcast on Thursday, November
3, at 5:00 p.m. ET to report third quarter 2022 financial results
and provide a corporate update.
This call is accessible via the below
teleconferencing numbers, followed by the reference ID:
94309191#.
- United States: 866 374
5140
- Canada: 866 455 3403
- United Kingdom: 808 238
9813
- France: 805 102 712
A live webcast of the call will be available on
the Investors & Media section of the Company’s website:
https://www.dbv-technologies.com/investor-relations/. A replay of
the presentation will also be available on DBV’s website after the
event.
About DBV TechnologiesDBV
Technologies is developing Viaskin™, an investigational proprietary
technology platform with broad potential applications in
immunotherapy. Viaskin is based on epicutaneous immunotherapy, or
EPIT™, and is DBV Technologies’ method of delivering biologically
active compounds to the immune system through intact skin. With
this new class of non-invasive product candidates, the Company is
dedicated to safely transforming the care of food allergic
patients. DBV Technologies’ food allergies programs include ongoing
clinical trials of Viaskin Peanut. DBV Technologies has global
headquarters in Montrouge, France, and North American operations in
Basking Ridge, NJ. The Company’s ordinary shares are traded on
segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345),
and the Company’s ADSs (each representing one-half of one ordinary
share) are traded on the Nasdaq Global Select Market (Ticker:
DBVT).
Investor Contact Anne PollakDBV
Technologies+1 857-529-2363anne.pollak@dbv-technologies.com
Media Contact Angela
MarcucciDBV Technologies+1
646-842-2393angela.marcucci@dbv-technologies.com
Viaskin and EPIT are trademarks of DBV
Technologies.
DBV Technologies (EU:DBV)
Gráfico Histórico do Ativo
De Fev 2024 até Mar 2024
DBV Technologies (EU:DBV)
Gráfico Histórico do Ativo
De Mar 2023 até Mar 2024